72P Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Year: 2024
Type: article
Abstract: Tebe is a bispecific fusion protein that binds gp100 presented by HLA-A*02:01 on melanoma cells and engages CD3 T-cells. While tebe has significantly improved overall survival in HLA-A*02:01+ mUM pts, clinical benefit after disease progression is limited. Here, we examine the efficacy and safety of adding CLT to tebe upon radiological progression with tebe alone.
Source: Immuno-Oncology Technology
Authors: T. Lim, K. Montazeri, A. Desilets, A.N. Shoushtari, R. Seedor, M. Orloff, T. Sato, M. Caplan, M. El-Ashmawy, B. Izar, S. Khan, R.D. Carvajal, I. Mehmi, O. Hamid, R. Sullivan
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374330